Pacira Biosciences, Inc. (PCRX) — SEC Filings
Pacira Biosciences, Inc. (PCRX) — 32 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 19 8-K, 5 10-Q, 3 DEFA14A.
View Pacira Biosciences, Inc. on SEC EDGAR
Overview
Pacira Biosciences, Inc. (PCRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Pacira BioSciences, Inc. reported a significant turnaround in Q3 2025, achieving net income of $5.432 million, a stark improvement from a net loss of $143.466 million in Q3 2024. For the nine months ended September 30, 2025, net income was $5.397 million, compared to a net loss of $115.601 million i
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 1 bullish, 30 neutral, 1 mixed. The dominant filing sentiment for Pacira Biosciences, Inc. is neutral.
Filing Type Overview
Pacira Biosciences, Inc. (PCRX) has filed 5 10-Q, 19 8-K, 2 DEF 14A, 3 DEFA14A, 1 10-K, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of PCRX's 28 recent filings, 0 were flagged as high-risk, 18 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $179,516,000 |
| Net Income | $5,432,000 |
| EPS | $0.12 |
| Debt-to-Equity | 0.78 |
| Cash Position | $147,589,000 |
| Operating Margin | N/A |
| Total Assets | $1,297,577,000 |
| Total Debt | $483,799,000 |
Key Executives
- Dr. David M. Stack
- Hubert L. "Skip" McKee
- Hubert "Hub" Davis
- John "Jack" W. Gallagher
- Dr. David J. Enders
- Ms. Susan L. Miller
- Dr. Michael J. Zinner
- Ms. Amy E. Paul
- David M. Stack
- Lewis G. Nelson, M.D.
Industry Context
Pacira BioSciences operates in the highly competitive pharmaceutical and biotechnology sector, focusing on non-opioid pain management and related therapies. The industry is characterized by significant R&D investment, stringent regulatory hurdles, and evolving market dynamics driven by innovation in areas like gene therapy. Companies often pursue strategic acquisitions to expand their product portfolios and technological capabilities.
Top Tags
corporate-governance (4) · 10-Q (4) · financials (4) · pharmaceuticals (4) · Pharmaceuticals (3) · sec-filing (3) · proxy-statement (3) · filing (3) · leadership-change (3) · Pacira BioSciences (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $5.432M | Significant turnaround from a net loss of $143.466 million in Q3 2024. |
| Total revenues for Q3 2025 | $179.516M | Increased from $168.573 million in Q3 2024, driven by product sales. |
| Goodwill impairment charge in Q3 2024 | $163.243M | Absence of this charge in Q3 2025 contributed to profitability. |
| Cash and cash equivalents at Sep 30, 2025 | $147.589M | Decreased from $276.774 million at Dec 31, 2024. |
| Revenue concentration from top three wholesalers in Q3 2025 | 77% | Indicates significant customer concentration risk. |
| Net cash used in financing activities for nine months ended Sep 30, 2025 | $317.975M | Primarily due to debt repayments and treasury stock purchases. |
| Repayment of 2025 convertible senior notes | $202.487M | Major component of cash used in financing activities. |
| Purchase of treasury stock for nine months ended Sep 30, 2025 | $100.080M | Contributed to cash outflow in financing activities. |
| Acquisition of GQ Bio Therapeutics GmbH | $16.702M | Strategic investment in gene therapy platform. |
| Basic and diluted net income per common share for Q3 2025 | $0.12 | Improved from a loss of $3.11 per share in Q3 2024. |
| SEC File Number | 001-35060 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 51-0619477 | Company's tax identification number. |
| Reporting Period | Q1 2025 | First quarter financial results |
| Prior Period | Q1 2024 | Comparison period for financial results |
| Acquisition Price | $100M | Cost to acquire assets from a privately held company. |
Frequently Asked Questions
What are the latest SEC filings for Pacira Biosciences, Inc. (PCRX)?
Pacira Biosciences, Inc. has 32 recent SEC filings from Jan 2024 to Nov 2025, including 19 8-K, 5 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PCRX filings?
Across 32 filings, the sentiment breakdown is: 1 bullish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Pacira Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pacira Biosciences, Inc. (PCRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pacira Biosciences, Inc.?
Key financial highlights from Pacira Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PCRX?
The investment thesis for PCRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pacira Biosciences, Inc.?
Key executives identified across Pacira Biosciences, Inc.'s filings include Dr. David M. Stack, Hubert L. "Skip" McKee, Hubert "Hub" Davis, John "Jack" W. Gallagher, Dr. David J. Enders and 5 others.
What are the main risk factors for Pacira Biosciences, Inc. stock?
Of PCRX's 28 assessed filings, 0 were flagged high-risk, 18 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Pacira Biosciences, Inc.?
Forward guidance and predictions for Pacira Biosciences, Inc. are extracted from SEC filings as they are enriched.